Titre
Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Ürün, Y.
Auteure/Auteur
Hussain, S.A.
Auteure/Auteur
Bakouny, Z.
Auteure/Auteur
Castellano, D.
Auteure/Auteur
Kılıçkap, S.
Auteure/Auteur
Morgan, G.
Auteure/Auteur
Mckay, R.R.
Auteure/Auteur
Pels, K.
Auteure/Auteur
Schmidt, A.
Auteure/Auteur
Doroshow, D.B.
Auteure/Auteur
Schütz, F.
Auteure/Auteur
Albiges, L.
Auteure/Auteur
Lopes, G.
Auteure/Auteur
Catto, JWF
Auteure/Auteur
Peters, S.
Auteure/Auteur
Choueiri, T.K.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
2687-8941
Statut éditorial
Publié
Date de publication
2020-08
Volume
6
Première page
1248
Dernière page/numéro d’article
1257
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
To understand readiness measures taken by oncologists to protect patients and health care workers from the novel coronavirus (COVID-19) and how their clinical decision making was influenced by the pandemic.
An online survey was conducted between March 24 and April 29, 2020.
A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist's decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.
Decision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic.
An online survey was conducted between March 24 and April 29, 2020.
A total of 343 oncologists from 28 countries participated. The median age was 43 years (range, 29-68 years), and the majority were male (62%). At the time of the survey, nearly all participants self-reported an outbreak in their country (99.7%). Personal protective equipment was available to all participants, of which surgical mask was the most common (n = 308; 90%). Telemedicine, in the form of phone or video encounters, was common and implemented by 80% (n = 273). Testing patients with cancer for COVID-19 via reverse transcriptase polymerase chain reaction before systemic treatment was not routinely implemented: 58% reported no routine testing, 39% performed testing in selected patients, and 3% performed systematic testing in all patients. The most significant factors influencing an oncologist's decision making regarding choice of systemic therapy included patient age and comorbidities (81% and 92%, respectively). Although hormonal treatments and tyrosine kinase inhibitors were considered to be relatively safe, cytotoxic chemotherapy and immune therapies were perceived as being less safe or unsafe by participants. The vast majority of participants stated that during the pandemic they would use less chemotherapy, immune checkpoint inhibitors, and steroids. Although treatment in neoadjuvant, adjuvant, and first-line metastatic disease was less affected, most of the participants stated that they would be more hesitant to recommend second- or third-line therapies in metastatic disease.
Decision making by oncologists has been significantly influenced by the ongoing COVID-19 pandemic.
Sujets
PID Serval
serval:BIB_8FE7781B5AAE
PMID
Open Access
Oui
Date de création
2020-08-17T09:23:06.362Z
Date de création dans IRIS
2025-05-21T01:44:17Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
32755479_BIB_8FE7781B5AAE.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
1.02 MB
Format
Adobe PDF
PID Serval
serval:BIB_8FE7781B5AAE.P001
URN
urn:nbn:ch:serval-BIB_8FE7781B5AAE6
Somme de contrôle
(MD5):cd998f5a5e271289dda421665987affb